Sotera Health Co

Sotera Health Company reported strong second-quarter 2026 financial results, with net income rising to $54 million, or $0.19 per diluted share, compared to $8 million, or $0.03 per diluted share in Q2 2025. Net revenues increased 9.2% to $321.375 million. The company also raised its full-year 2026 outlook for both net revenues and Adjusted EBITDA growth, citing strong first-half performance and confidence in the remainder of the year.

Sotera Health Company announced strong financial results for Q2 2026, with net revenues increasing 9.2% and net income rising significantly to $54 million. The company also reported a 10.0% increase in Adjusted EBITDA and a 30% rise in Adjusted EPS. Following this strong performance, Sotera Health raised its full-year 2026 outlook for both net revenues and Adjusted EBITDA growth, reflecting confidence in continued execution across its business units.

Sotera Health Company entered into Amendment No. 7 to its First Lien Credit Agreement, refinancing approximately $1.42 billion in term loans. The amendment reduces the interest rate spread by 0.25% and sets the new applicable interest rate margin at Adjusted Term SOFR plus 2.25%. The Repriced Term Loans mature on May 30, 2031, and include a 1.00% soft call premium for certain repricing transactions within six months.

On May 13, 2026, Sotera Health Company's Stockholders Agreement, dated November 19, 2020, terminated following the completion of an offering where affiliates of Warburg Pincus LLC and GTCR LLC (the "Sponsors") sold all their 31,838,253 shares of common stock. The shares were sold at $15.168 per share, with the Company not issuing any shares or receiving any proceeds from the transaction. As a result, the Sponsors no longer own common stock and their special corporate governance rights, including the right to designate directors, have ended.

Sotera Health Company announced a secondary offering of 31,838,253 shares of its common stock. The shares are being offered for sale by certain affiliates of Warburg Pincus LLC and GTCR LLC, who are the selling stockholders. Sotera Health will not be selling any shares in this offering and will not receive any proceeds, though it will cover the offering expenses.

Sotera Health reported a net income of $26.6 million for the first quarter of 2026, a significant turnaround from a net loss of $13.3 million in the prior year's quarter. Total net revenues increased to $280.0 million, up from $254.5 million year-over-year, with basic earnings per share reaching $0.09. The company also provided updates on ongoing ethylene oxide tort litigation in California and Georgia.

Sotera Health announced a leadership transition, appointing Alton Shader as the new Chief Executive Officer and a Class II director, effective May 26, 2026. Current CEO Michael B. Petras, Jr. will transition to Executive Chairman. Concurrently, the company reported strong first-quarter 2026 financial results, with net revenues increasing 10.0% to $280.045 million and net income reaching $27 million, a significant improvement from a net loss in the prior year. Sotera Health also reaffirmed its full-year 2026 outlook, projecting continued growth in net revenues and Adjusted EBITDA.

Sotera Health reported a strong start to 2026 with Q1 net revenues increasing 10.0% to $280 million and net income reaching $27 million, a significant improvement from a net loss in Q1 2025. Adjusted EPS rose 29% to $0.18, and Adjusted EBITDA increased 10.5%. The company reaffirmed its full-year 2026 financial outlook, and separately announced a planned CEO transition.

Sotera Health Company announced its plan to release first-quarter financial results for the period ended March 31, 2026, before market open on Tuesday, May 5, 2026. Following the release, management will host a conference call at 9:00 a.m. Eastern Daylight Time to discuss the operating and financial results. A live webcast and accompanying materials will be accessible through the Investor Relations section of the company's website.